Neuropeptides in the Humane Intra- og Extracerebral Circulation.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00399633|
Recruitment Status : Completed
First Posted : November 15, 2006
Last Update Posted : May 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Healthy Migraine||Drug: sumatriptan||Not Applicable|
The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system.
The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||16 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Neuropeptides in the Humane Intra- og Extracerebral Circulation - in Relation to Sumatriptan in Healthy Volunteers.|
|Study Start Date :||January 2007|
|Actual Primary Completion Date :||April 2007|
|Actual Study Completion Date :||April 2007|
- Blood concentration of vasoactive intestinal polypeptide (VIP),
- calcitonin gene-related protein (CGRP), pituitary adenylate cyclase
- activating peptide (PACAP,) and the prostanoids
- 6-keto-PGF1α, PGE2, PGD2 and PGF2α, sampled from different
- venous catheters.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00399633
|Danish Headache Center|
|Glostrup, Copenhagen, Copenhagen, Denmark, 2600|
|Principal Investigator:||Jakob Møller Hansen, MD||Danish Headache Center|